Data_Sheet_1_Immune and Neuroendocrine Trait and State Markers in Psychotic Illness: Decreased Kynurenines Marking Psychotic Exacerbations.docx by Livia De Picker (8319105)

“…Normalization of KA and 3-HK levels between admission and follow-up corresponded to a larger improvement of negative symptoms (r = 0.5, p < 0.030) A reverse association was found between relative improvement of SDST scores and decreasing KA levels (r = 0.5, p < 0.010).…”

S4 Fig - by R. J. S. D. Heine (17889199)

“…</p><p>Discussion</p><p>The estimated CBPs are consistently lower than Dutch list prices for pembrolizumab (€2,861), mainly resulting from larger patient populations in registered indications. …”

S1 Fig - by R. J. S. D. Heine (17889199)

“…</p><p>Discussion</p><p>The estimated CBPs are consistently lower than Dutch list prices for pembrolizumab (€2,861), mainly resulting from larger patient populations in registered indications. …”

S5 Fig - by R. J. S. D. Heine (17889199)

“…</p><p>Discussion</p><p>The estimated CBPs are consistently lower than Dutch list prices for pembrolizumab (€2,861), mainly resulting from larger patient populations in registered indications. …”

S3 Fig - by R. J. S. D. Heine (17889199)

“…</p><p>Discussion</p><p>The estimated CBPs are consistently lower than Dutch list prices for pembrolizumab (€2,861), mainly resulting from larger patient populations in registered indications. …”

S6 Fig - by R. J. S. D. Heine (17889199)

“…</p><p>Discussion</p><p>The estimated CBPs are consistently lower than Dutch list prices for pembrolizumab (€2,861), mainly resulting from larger patient populations in registered indications. …”

Input parameters for the base-case analysis. by R. J. S. D. Heine (17889199)

“…</p><p>Discussion</p><p>The estimated CBPs are consistently lower than Dutch list prices for pembrolizumab (€2,861), mainly resulting from larger patient populations in registered indications. …”

S2 Fig - by R. J. S. D. Heine (17889199)

“…</p><p>Discussion</p><p>The estimated CBPs are consistently lower than Dutch list prices for pembrolizumab (€2,861), mainly resulting from larger patient populations in registered indications. …”

S1 Data - by R. J. S. D. Heine (17889199)

“…</p><p>Discussion</p><p>The estimated CBPs are consistently lower than Dutch list prices for pembrolizumab (€2,861), mainly resulting from larger patient populations in registered indications. …”

CBP per cumulative year for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

CBP per cumulative indication for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

Implementation of indication-based pricing (10^th scenario) for daratumumab and pembrolizumab. by R. J. S. D. Heine (17889199)

Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation. by R. J. S. D. Heine (17889199)

Outcome variable descriptive statistics. by Kristen S. Regenauer (13842386)

“…Depression stigma was lower than SU stigma at both timepoints and did not significantly decrease after training. …”

Demographic & job characteristics. by Kristen S. Regenauer (13842386)

“…Depression stigma was lower than SU stigma at both timepoints and did not significantly decrease after training. …”

Training feedback. by Kristen S. Regenauer (13842386)

“…Depression stigma was lower than SU stigma at both timepoints and did not significantly decrease after training. …”

Study flow. by Kristen S. Regenauer (13842386)

“…Depression stigma was lower than SU stigma at both timepoints and did not significantly decrease after training. …”

Post-RARP urinary continence recovery stratified by voided volume change. by Yuta Takeshima (818627)

“…A statistically significant difference was found for both curves, with a larger decrease in voided volume exhibiting a lower continence rate (log-rank test: P value = 0.011 and 0.008, respectively). …”

Correlation and principal component analysis. by Jie Wei (264772)

S1 Raw data - by Rashid Mussa Mruma (17980110)

“…<i>036</i>) and vertical directions (mean difference = 0.37 cm, p = 0.003). Patients’ age was a significant predictor of random errors whereby the magnitude of random error decreased with increasing age.…”